Ceftolozane

CHEMBL2103872 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

666.7 g/mol

LogP

-3.2

Phase

4

The active component of a newer beta-lactam antibiotic designed with enhanced activity against Pseudomonas aeruginosa, typically used in combination with the beta-lactamase inhibitor tazobactam. It is indicated for complicated urinary tract and intra-abdominal infections as well as hospital-acquired pneumonia. It provides an important option for multidrug-resistant Pseudomonas infections.

Molekularmasse

666,7000 g/mol

LogP

-3,20

TPSA

356,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Hematology Infectious Disease Oncology Type 2 Diabetes

Wirkmechanismus

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

Cn1c(N)c(NC(=O)NCCN)c[n+]1CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OC(C)(C)C(=O)[O-])c3nsc(N)n3)[C@H]2SC1

InChI

InChI=1S/C23H30N12O8S2/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42)/b31-11-/t12-,18-/m1/s1

Molecular Formula

C23H30N12O8S2

HBD / HBA

7 / 16

Rotierbare Bindungen

11

Schwere Atome

45

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The active component of a newer beta-lactam antibiotic designed with enhanced activity against Pseudomonas aeruginosa, typically used in combination with the beta-lactamase inhibitor tazobactam. It is indicated for complicated urinary tract and intra-abdominal infections as well as hospital-acquired pneumonia. It provides an important option for multidrug-resistant Pseudomonas infections.

Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), preventing transpeptidation and cross-linking of peptidoglycan chains. This weakens the bacterial cell wall, leading to osmotic lysis and cell death.

Yes, Ceftolozane is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2103872. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 53234134. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Ceftolozane auf PillFYI

Struktur

Schnelldaten

Formel: C23H30N12O8S2
Synonyme: 1

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.